Vericel Corp. (VCEL)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 07, 2025

$58.08

P/E Ratio

929.28

Market Cap

$2.87B

Jan 22, 2024Feb 26, 2024Apr 1, 2024May 2, 2024Jun 5, 2024Jul 9, 2024Aug 8, 2024Sep 12, 2024Oct 17, 2024Nov 21, 2024Jan 7, 2025$30.00$40.00$50.00
  • APAM
Description

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Metrics

Overview

  • HQCambridge, MA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerVCEL
  • Price$58.08+0.82%

Trading Information

  • Market cap$2.87B
  • Float99.09%
  • Average Daily Volume (1m)339,495
  • Average Daily Volume (3m)377,456
  • EPS$0.08

Company

  • Revenue$226.84M
  • Rev growth (1yr)27.04%
  • Net income-$0.90M
  • Gross margin71.93%
  • EBITDA margin-1.97%
  • EBITDA-$1.14M
  • EV$2.05B
  • EV/Revenue9.05
  • P/E929.28
  • P/S12.57
  • P/B11.11
Documents